Explaining the relationship and possible benefits of stem cell therapy for Lyme Disease.
December 13, 2021
Dec 13, 2021
Medical Director | DVC Stem
Explaining the relationship and possible benefits of stem cell therapy for Lyme Disease.
Innovative stem cell treatments may potentially be excellent alternative therapies for the treatment of Lyme and Post-treatment Lyme Disease Syndrome (PTLDS) symptoms. Mesenchymal Stem Cells have potent anti-inflammatory and immunomodulatory effects. This ability to positively alter the immune system as well as reduce inflammation may be able to reduce the severity of symptoms in patients with Lyme Disease. When applied systemically through IV deployment, Mesenchymal Stem Cells can travel the body, seeking out inflammation and damaged tissue for repair.
Patients can expect a reduction in inflammation-related symptoms, reduction in pain, regulation of the immune system, and assistance in eliminating the Borrelia bacteria. Additionally, the effects of treatment may last for lengthy periods, potentially even halting the progression of symptoms.
Lyme Disease is an infection caused by the bacterium Borrelia Burgdorferi. It is an illness that is characterized by a robust immune response in the body, causing debilitating symptoms.
These symptoms of Lyme can vary by the stage of the disease and may progressively get worse as the disease advances. The symptoms of Lyme Disease include:
If left untreated Lyme Disease can lead to more severe symptoms such as:
Lyme Disease is transmitted to humans from tick bites. It is transmitted from infected ticks of the genus Ixodes (a genus of hard-bodied ticks that may transmit pathogenic microorganisms including the bacterium Borrelia Burgdorferi).
Early signs of Lyme Disease include:
Education and awareness is the most valuable form of prevention against Lyme Disease. Prevention measure may include;
Avoidance may be the most effective way to prevent a tick bite. The highest concentration of ticks are found in damp, wooded areas. It may be beneficial to avoid these areas, but if one cannot, stick to marked trails and paths.
“The New York State Department of Health’s public-affairs office recommends doing “a final, full-body tick check at the end of the day, and also check children and pets,” in order to protect against ticks and tick-borne illness.”
No, Lyme disease is not contagious; there is no evidence that has shown transmission from person to person. A person cannot get infected with Lyme Disease by touching, kissing, or engaging in intercourse with another person with Lyme Disease.
Once diagnosed, an antibiotic regimen is usually prescribed. The route of administration, strength of the antibiotic, and duration of therapy are highly dependent on the state of the progression of the disease. The earlier the patient receives treatment, the higher the chance of success.
John O Meyerhoff, MD, outlines the standard antibiotic regimes for both adults and children below:
“Doxycycline, amoxicillin, cefuroxime axetil, or phenoxymethylpenicillin is recommended for the treatment of adult patients with early localized or early disseminated Lyme disease associated with erythema migrans, in the absence of specific neurologic manifestations or third-degree heart block.” (2)
“Antibiotics recommended for children include amoxicillin, cefuroxime axetil, and phenoxymethylpenicillin; in children, eight years and older, doxycycline may be used. Because of its cost, cefuroxime axetil is reserved for patients unable to take amoxicillin or doxycycline” (2)
If treated early, yes, Lyme Disease can be cured with the proper antibiotic regimen. However, if the condition is left untreated, symptoms such as; arthritis, heart, and nervous system issues can occur. These symptoms can become increasingly difficult to impede and may require an alternative form of therapy.
PTLDS stands for Post-treatment Lyme Disease Syndrome. This syndrome is characterized by a continuation of the symptoms of Lyme Disease after receiving antibiotics. These symptoms can include:
“According to the New England Journal of Medicine, approximately 10 to 20 percent of people who are treated with the recommended antibiotics will have disease symptoms that persist after they complete treatment.”
Mesenchymal Stem Cells may be a viable treatment option for Post Treatment Lyme Disease Syndrome (PTLDS).
Stem cells have been proven to have strong anti-inflammatory properties. Through the use of large cell quantity transplants, the youthful stem cells have a regulatory nature on the body. They can reduce the immuno-effect that the body cannot regulate on its own.
Specifically, Mesenchymal Stem Cells (MSCs) can inhibit the overproduction and use of T-cells in the body. This effect occurs without compromising the body’s natural immune system and leaving the patient vulnerable to disease.
The effect of the transplant is a return of the body to normal immune function and a drastic reduction in a patient’s inflammation markers. This anti-inflammatory effect can last for years at a time without the need for another transplant.
What this means for patients with autoimmune and degenerative diseases is a natural solution to their symptoms, a respite from discomfort, and an overall increase in quality of life.
Additionally, not only will the body better be able to heal damaged tissue with the inflammation reduced, but the stem cells will also assist is more rapid healing within the body.
A patient case study held by Geeta Shroff found:
“Therapy with stem cells might emerge as an effective and safe treatment for patients with both Multiple Sclerosis and Lyme Disease.”
A 30 year old female found to have Lyme Disease was treated with stem cells. She was having difficulty walking, spasticity in lower limbs, unable to stand without support, weakness in arms, and joint pains.
“Following the first treatment phase, the patient reported remarkable improvement in her lower limb strength, decreased spasticity, and had no longer fatigue issues. Also, she was able to walk upright now with support. After her second visit, improvement in muscle strength, movement of the left upper arm, spasticity of left lower, and left upper limb was observed. The patient was able to walk independently for up to 40–50 minutes around the room. An improvement was observed in parameters like muscle weakness, walking distance, balance, fatigue, pain, blurring of eyes, and deformity.” (4)
Stem cell therapy may be able to help improve PTLDS symptoms over a significant period of time. Patients may experience an improvement in balance, energy levels, strength, coordination, and motivation. Stem cell therapy may also potentially be an effective Chronic Lyme Disease treatment.
DVC Stem uses cord tissue-derived mesenchymal stem cells ethically sourced from AATB certified, US-donated, full-term human umbilical cords. We administer over 300 million cells that are all thoroughly tested for viability before treatment. These cells are NOT a blood product; therefore, it is extremely safe and does not require HLA or phenotypic matching.
All patients undergo therapy in our VIP treatment room located within our advanced clinic. Patients are under constant supervision from both our medical director and the supporting medical team.
We typically recommend patients stay a minimum of 4 days in Grand Cayman for treatment.
1) Department of Health. “Proper Precautions Can Help Prevent Lyme Disease and the Spread of Tick-Borne Illnesses.” DOH, DEC and State Parks Remind New Yorkers to Protect Against Ticks, Department of Health, Apr. 2019, www.health.ny.gov/press/releases/2019/2019-05-24_lyme_and_ticks.htm.
2) Meyerhoff, John D, and Herbert S Diamond. “Lyme Disease Treatment & Management: Approach Considerations, Treatment of Early Lyme Disease, Lyme Arthritis.” Lyme Disease Treatment & Management: Approach Considerations, Treatment of Early Lyme Disease, Lyme Arthritis, 12 Nov. 2019, emedicine.medscape.com/article/330178-treatment#d7.
3) Melia, Michael T., and A. Berende. “Time for a Different Approach to Lyme Disease and Long-Term Symptoms: NEJM.” New England Journal of Medicine, 31 Mar. 2016, www.nejm.org/doi/10.1056/NEJMe1502350.
4) Shroff, Geeta. “Transplantation of Human Embryonic Stem Cells in Patients with Multiple Sclerosis and Lyme Disease.” The American Journal of Case Reports, International Scientific Literature, Inc., 13 Dec. 2016, www.ncbi.nlm.nih.gov/pmc/articles/PMC5156555/.
About the author
Dr. Cona has been performing stem cell therapy for over 10 years. He is a member of the World Academy of Anti-Aging Medicine (WAAAM). He is also a recognized member of the British Medical Association, the General Medical Council (UK), the Caribbean College of Family Physicians, and the American Academy of Family Physicians. He is the Medical Director for DVC Stem a world-renowned stem cell therapy clinic located in Grand Cayman.
Are you a candidate for stem cell treatment?
Complete our brief online application to find out if our IRB-approved mesenchymal stem cell treatment is right for you.Apply for treatment
You might also like...
Eddie "The Beast" Hall received an infusion of over 300 million cord tissue-derived mesenchymal stem cells at DVC Stem.
The borders of the Cayman Islands are in a phased reopening process, which will expand within the next couple of months. This means that the airport is open but travel must be approved by the Cayman Islands Government & all visitors must participate in a mandatory 10 - 14 day quarantine.
Stem cell therapy is a non-invasive treatment that aims to replace damaged cells within the body. Mesenchymal stem cell therapy can be deployed systemically via IV or injected locally to target specific sites, depending on patient needs.
Stem cell therapy has become increasingly popular as a therapeutic opportunity for Rheumatoid Arthritis patients due to mesenchymal stem cells unique capacity to modulate the immune system.
This article will explain what Haematopoietic stem cell transplantation (HSCT) involves, its benefits/risks, and how it may or may not be helpful for certain neurological conditions. It will also compare mesenchymal stem cell therapy (MSCT) with HSCT including the benefits and risks of both treatments.
DVC STEM, GRAND CAYMAN